MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease_Hepatitis
Conatus Pharmaceuticals (NASDAQ:CNAT)
Organization & Developments: Conatus
Parents
Conatus Pharmaceuticals (NASDAQ:CNAT)
Children
2016: Biotech Forum Daily Digest: Acadia, Collaboration Deals Boost Akebia And Conatus. Spotlight On Anika Therapeutics - iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)
2016: Conatus Pharma Doubles On Novartis NASH Liver Drug Licensing Deal
2017: Biotech Forum Daily Digest: Trump Dings Biotech, What Now For Conatus Pharmaceuticals? - Conatus Pharmaceuticals (NASDAQ:CNAT)
2017: Novartis enter agreement with Conatus for NASH treatment
2017: Your Daily Pharma Scoop: Conatus Looks Undervalued, Teva Announces Restructuring, Bristol-Myers Signs Licensing Agreement - Conatus Pharmaceuticals (NASDAQ:CNAT)
2018: Conatus Falls On Phase 2 Data, But There Is More To The Story_seekingalpha.com
2018: Conatus Pharmaceuticals: Upcoming Phase 2b Liver Results And Other Pipeline Prospects Make It A Compelling Buy - Conatus Pharmaceuticals (NASDAQ:CNAT)
2018: Conatus: Was That Trial A Total Failure?_seekingalpha.com
2018: Conatus: What's Next For This Small-Cap Potential NASH Play?_seekingalpha.com
2018: Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study
2018: NASH Series 6 - Diagnosis: Looking For The Right Method, And Conatus Pharmaceuticals_seekingalpha.com
2018: Your Daily Pharma Scoop: Conatus Rallies, Ionis Data, Reata's Omaveloxolone Fails In Mid-Stage Study - Conatus Pharmaceuticals (NASDAQ:CNAT)
2019: 8 programs to watch in NASH: Four letters and a multibillion-dollar opportunity
2019: Conatus Is Gearing Up For A Compelling 2019 With Multiple Catalysts_seekingalpha.com
2019: Conatus to Slash Staff, Consider Sale After NASH Trial Failures
Conatus is a so-called virtual company, employing 11 workers and contracting with outside service providers for most of the activities involved in drug development.
Drugs developed by Conatus could be useful in chronic viral hepatitis, liver transplant failure, and liver disease related to ob
Pharmaceutical company in-licensing and developing clinical stage drugs for the treatment of liver disease.
The hepatitis C compound is currently in multiple mid-stage clinical trials. (2011)
Jumps
*Key People: Conatus
Finance & Acquisition: Conatus